资源 » 参考数据库 » 客户发表文献

至今，GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次，处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果，再次证明GenScript 有能力帮助业内科学家Make research easy.

In Vivo Delivery of a DNA-Encoded Monoclonal Antibody Protects Non-human Primates against Zika Virus.

Mol. Ther.. 2019;

EsquivelRianne N，PatelAmi，KudchodkarSagar B，ParkDaniel H，StettlerKarin，BeltramelloMartina，AllenJeffrey W，MendozaJaness，RamosStephanie，ChoiHyeree，BorolePiyush，AsijaKanika，BahMamadou，ShaheenShareef，ChenJing，YanJian，DurhamAmy C，SmithTrevor R F，BroderickKate，GuibingaGhiabe，MuthumaniKar，CortiDavide，HumeauLaurent，WeinerDav

Products/Services Used	Details	Operation
Custom Vector Construction	… A LALA variant, containing mutations at L234A and L235A to abrogate Fc gamma receptor engagement, was also created. 11 The optimized DNA transgenes were then synthesized de novo (GenScript, Piscataway, NJ, USA) and inserted into the DMAb expression vector …	Get A Quote

摘要

Zika virus (ZIKV) infection is endemic to several world regions， and many others are at high risk for seasonal outbreaks. Synthetic DNA-encoded monoclonal antibody (DMAb) is an approach that enables in vivo delivery of highly potent mAbs to control infections. We engineered DMAb-ZK190， encoding the mAb ZK190 neutralizing antibody， which targets the ZIKV E protein DIII domain. In vivo-delivered DMAb-ZK190 achieved expression levels persisting >10 weeks in mice and >3 weeks in non-human primate (NHPs)， which is protective against ZIKV infectious challenge. This study is the first demonstration of infectious disease control in NHPs following in vivo delivery of a nucleic acid-encoded antibody， supp... More